Evaluation on biocompatibility of β-type titanium alloys

The aim of the study is to evaluate the in vivo biocompatibility to two novel β-type titanium alloys: TLE (Ti-(3-6)Zr-(2-4)Mo(24-27)Nb), TLM 2(Ti-(1.5-4.5) Zr-(0.5-5.5) Sn-(1.5-4.4)Mo-(23.5-26.5)Nb). The two titanium alloys (TLE, TLM2) and the contrast alloy (Ti-6Al-4V) were implanted subcutaneously and intramuscularly in rabbits. According to GB/T16886.6-1997 standard, the macroscopic observations and histologic examination were carried out for 1, 2, 6, 12 and 24 weeks after the implantation. Result show that the degree of inflammation presents no difference between the two new β-type titanium alloys (TLE, TLM 2) and the contrast alloy (Ti-6Al-4V), the thicknesses of the capsules of the two novel β-type titanium alloys are thinner than those of the contrast alloy. The two new β-type Titanium alloys (TLE, TLM 2) have good biocompatibility.